Moderna, Inc.

Moderna, Inc.

MRNANYSE / NASDAQHealthcareLarge cap

$195.00-$4.33 (-2.2%)

Last close · Data as of Nov 20, 2026

Market cap
$20.5B
P/E
-7.3x
EV / EBITDA
-7.5x
Revenue
$1.9B
Net margin
-146.8%
ROCE
-29.7%

This period includes a one-day price step on 19 Aug 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Moderna, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-19.4%
3M
+46.3%
6M
Hidden
1Y
Hidden
5Y
Hidden
  • This period includes a one-day price step on 19 Aug 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

This period includes a one-day price step on 19 Aug 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$4.33 (-2.2%) from $199.33 to $195.00 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in MRNA, bought on each weekday since 2021.

News & filings

What Moderna filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 2.8 billion US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 3.29 times current liabilities.
  • This period includes a one-day price step on 19 Aug 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.

Read moreShow less

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Shares outstanding
394.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$20.5B
P/E
-7.3x
P/B
2.4x
EV / EBITDA
-7.5x
EV / Sales
10.0x
P/S
10.7x
52-week high
Hidden
52-week low
Hidden

Profitability

Operating margin
-159.9%
Net margin
-146.8%
EBITDA margin
-132.3%
ROE
-32.6%
ROCE
-29.7%
ROA
-22.9%
Asset turnover
0.16

Growth

Revenue
$1.9B
Revenue growth, 1Y
-39.9%
Revenue CAGR, 3Y
-53.3%
Net profit growth, 1Y
-20.8%
Free cash flow
-$2.1B

Solvency

Current ratio
3.29
Debt / Equity
0.15
Debt / Assets
0.11
CFO / Net profit
0.66
Cash / Market cap
12.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$1.9B
Cost of revenue$868.0M
Gross profit$1.1B
Operating expenses$4.1B
Research and development$3.1B
Selling, general and administrative$1.0B
Operating income-$3.1B
Interest and other$306.0M
Pretax income-$2.8B
Tax and other$54.0M
Net income-$2.8B

Revenue and net profit

Revenue fell 39.9% in FY2025; net profit is the dashed line.

Moderna, Inc. revenue and net profit by fiscal year
Moderna, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$18.9B$8.4B
FY2023$6.8B-$4.7B
FY2024$3.2B-$3.6B
FY2025$1.9B-$2.8B

Cash flows

FY2025: -$1.9B from operations, -$2.1B free after investment (dashed).

Moderna, Inc. operating and free cash flow by fiscal year
Moderna, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$5.0B$4.6B
FY2023-$3.1B-$3.8B
FY2024-$3.0B-$4.1B
FY2025-$1.9B-$2.1B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.9B-39.9%1Y
EBITDA
-$2.5B
Net profit
-$2.8B
Cash from operations
-$1.9B
Free cash flow
-$2.1B
Revenue CAGR, 3Y
-53.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.9B-$2.5B-$2.8B-$2.1B-32.6%-39.9%-20.8%

Monthly returns

Month-by-month returns of MRNA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$12.3B
Liabilities$3.7B
Equity$8.7B
Paid-in capital$1.4B
Retained earnings$7.2B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; MRNA highlighted.

P/E against peers

MRNA has no positive P/E; the peer median is 24.4x.

Not shown (no positive earnings and no EV / Sales): Moderna, Inc., Insmed Incorporated, Viatris Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Moderna, Inc.MRNAthis company$20.5B-7.3x2.4x-32.6%-7.5x
Mettler-Toledo International Inc.MTD$23.9B27.4x—-3676.8%20.9x
Insmed IncorporatedINSM$22.7B-17.8x30.8x-172.8%—
West Pharmaceutical Services, Inc.WST$22.4B45.4x7.1x15.5%28.4x
Quest Diagnostics IncorporatedDGX$21.7B21.9x3.0x13.8%12.9x
Labcorp Holdings Inc.LH$21.4B24.4x2.5x10.2%13.6x
STERIS plcSTE$20.7B26.5x2.9x10.9%14.0x
Incyte CorporationINCY$20.2B15.7x3.9x24.9%9.8x
Viatris Inc.VTRS$18.5B—1.3x-23.9%—
Peer median—24.4x3.0x10.5%13.8x

Year-to-date ROI

MRNA since 1 January, against earlier years.

Historical volatility

MRNA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Moderna, Inc. operating margin by fiscal year
Moderna, Inc. operating margin by fiscal year
DateOperating margin
FY202249.9%
FY2023-62.8%
FY2024-123.3%
FY2025-159.9%
LineFY2025
Cost of revenueCost Of Revenue$868.0M
Gross profitGross Profit$1.1B
Operating expensesOperating Expense$4.1B
Research and developmentResearch And Development$3.1B
Selling, general and administrativeSelling General And Administration$1.0B
Other operating expensesOther Operating Expenses-$22.0M
Total expensesTotal Expenses$5.0B
Pretax incomePretax Income-$2.8B

Learn while you research

Academy chapters picked for Moderna, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →